Lactylation, a post-translational modification characterized by the addition of a lactate moiety to target proteins, has garnered attention for its potential role in cellular signaling. This modification stems from the metabolic byproduct of glycolysis, linking cellular metabolism to gene expression and regulatory mechanisms. Shou and colleagues unveil how lactylation can influence miRNA activity, an area that has gone largely unexplored in the context of cancer therapy resistance. This connection suggests a complex interplay between metabolic pathways and the regulatory networks governing cancer progression and treatment responsiveness.

In their research, the authors first investigate the biochemical mechanisms underlying lactylation and its ability to modify specific miRNAs that have been implicated in cancer therapy. Through precise experimental manipulations, they demonstrate how lactate levels influence miRNA expression patterns, subsequently affecting the cellular responses to anti-cancer treatments. This finding highlights a crucial link between metabolic states and therapeutic efficacy, suggesting that cancer cells may adapt to treatment by altering their miRNA profiles through lactylation.

Furthermore, the study identifies specific miRNAs that are significantly regulated by lactylation. Among these are miRNAs that play pivotal roles in various tumorigenic processes, such as proliferation, apoptosis, and metastatic potential. By targeting these miRNAs, either through direct modification or utilizing novel therapeutic approaches, researchers can potentially enhance the effectiveness of existing therapies. This line of inquiry positions lactylation as a key player in the adaptive responses of cancer cells, rendering them more resilient against conventional treatments.

In their quest for understanding, Shou et al. also explore the broader implications of lactylation on the tumor microenvironment. Cancer cells exist in a highly dynamic and heterogeneous environment, where various factors including nutrient availability, pH, and metabolic state can profoundly influence their behavior. The authors propose that lactate signaling, facilitated by lactylation, could alter the interaction between cancer cells and their surrounding stroma. This alteration might contribute to an ecosystem that promotes therapy resistance, highlighting the need for a holistic approach in cancer treatment that considers both cancer cell metabolism and the microenvironment.

Moreover, the researchers underscore the potential of lactylation as a therapeutic target. By employing small molecules or biological agents that inhibit lactylation pathways, they have demonstrated the feasibility of manipulating miRNA expression levels in preclinical models. Such interventions could disrupt the ability of cancer cells to adapt to therapy, ultimately improving patient outcomes. This approach could represent a paradigm shift in how we understand and combat cancer resistance mechanisms, moving beyond traditional ideas that focus solely on the cancer cell itself.

The implications of this research extend to the realm of personalized medicine as well. Understanding how individual patients metabolically respond to treatments and how lactylation affects their unique miRNA profiles can inform the development of tailored treatment plans. This personalized approach not only holds promise for improving therapeutic efficacy but also for mitigating adverse effects associated with systemic treatments. By integrating lactylation and miRNA regulation into patient care strategies, oncologists could optimize therapy for each individual based on their metabolic state.

In considering the clinical translations of these findings, Shou et al. stress the importance of further investigations to validate their observations in clinical settings. Clinical trials that examine the relationship between lactylation status, miRNA profiles, and treatment responses could provide a wealth of data that shapes future therapeutic protocols. Such endeavors will necessitate multidisciplinary collaboration among oncologists, biochemists, and molecular biologists to foster a deeper understanding of this complex interplay.

As researchers continually unlock the intricate mechanisms of cancer therapy resistance, the role of lactylation emerges as an exciting new frontier. The study by Shou and colleagues serves as a pivotal entry point into this realm, setting the stage for future investigations that could transform the landscape of cancer treatment. By understanding and leveraging the lactylation-mediated regulation of miRNAs, researchers may uncover novel strategies to outsmart cancer and thwart its insidious ability to resist therapy.

While the path toward translating these findings into clinical practice remains fraught with challenges, the potential rewards are immense. As scientists unearth the connections between metabolism, epigenetics, and gene regulation, the hope is that these insights will culminate in more effective, less toxic cancer therapies. The journey of understanding lactylation’s influence on miRNA regulation, as delineated by Shou et al., represents a significant step forward in the ongoing battle against cancer, a battle that continuously demands innovative approaches and fresh perspectives.

The ongoing exploration of lactylation as a regulator in cancer therapy could lead not only to improved treatment regimens but also to a deeper understanding of cancer biology. As this research unfolds, the scientific community remains hopeful that these insights will not only advance our knowledge of cancer mechanisms but also empower clinicians to provide better, more effective care for patients facing this formidable disease.

In conclusion, the work of Shou et al. underscores the importance of exploring novel post-translational modifications like lactylation in the quest to unravel the complexities of cancer therapy resistance. As we stand on the cusp of new discoveries, the merging of biochemistry, molecular biology, and clinical research opens up a myriad of possibilities to combat one of humanity’s most daunting challenges. The journey is far from over, but with each step forward, we come closer to turning the tide against cancer.

Subject of Research: Lactylation-mediated miRNA regulation in cancer therapy resistance.

Article Title: Lactylation-mediated miRNA regulation in cancer therapy resistance.

Article References:

Shou, Y., Liu, R., Xiong, H. et al. Lactylation-mediated miRNA regulation in cancer therapy resistance.
J Transl Med 23, 941 (2025). https://doi.org/10.1186/s12967-025-06959-5

Image Credits: AI Generated

DOI: https://doi.org/10.1186/s12967-025-06959-5

Keywords: Lactylation, miRNA, cancer therapy resistance, post-translational modifications, cancer biology, metabolism, personalized medicine.

Within the tumor microenvironment (TME), the metabolic reprogramming of cancer cells towards high glycolytic flux results in significant lactic acid and proton export, chiefly via monocarboxylate transporter 4 (MCT4). This export acidifies the extracellular space to a pH estimated at 6.5 to 6.8, profoundly impacting surrounding cells and molecular processes. Acidification not only degrades the extracellular matrix, facilitating invasion and metastasis, but also impairs the efficacy of chemotherapeutic drugs, particularly weak-base agents, by protonation-induced neutralization, which reduces their cellular uptake. This acidic milieu thus creates a physical and biochemical barrier against conventional therapies, presenting a formidable challenge for oncologists.

Paradoxically, cancer cells are adept at recycling the very lactic acid they expel. Through monocarboxylate transporter 1 (MCT1), tumor cells re-import lactate to fuel mitochondrial oxidative metabolism. This lactate utilization fosters oxidative phosphorylation within the tricarboxylic acid (TCA) cycle and promotes NADPH production via isocitrate dehydrogenase 1 (IDH1), contributing to redox balance and anabolic processes required for sustained proliferation. Notably, lactate also stimulates post-translational lactylation of DNA repair proteins such as NBS1 and MRE11. This lactylation enhances genomic stability and fortifies cancer cells against chemotherapeutic DNA damage, thereby contributing to the development of treatment resistance.

The immunosuppressive effects of lactate and its associated acidification in the TME manifest distinctly across immune cell populations. Tumor-associated macrophages (TAMs), through signaling via GPR81 and GPR132, are reprogrammed into an M2-like phenotype characterized by high IL-10 production and secretion of chemokines such as CCL17. This phenotype supports tumor metastasis and suppresses effective immune responses. Dendritic cells exposed to acidic stress experience disruption of TLR3 and STING pathways, resulting in impaired antigen presentation and accelerated antigen degradation. This functional impairment hampers the priming of adaptive immune responses vital for tumor surveillance.

Natural killer (NK) cells encounter profound functional suppression within the acidic TME. Intracellular acidification triggers apoptotic pathways leading to loss of cytotoxic granules and abrogation of interferon-gamma (IFN-γ) secretion, critical components of their tumoricidal repertoire. Intriguingly, tumor-intrinsic factors such as SIX1-mediated overexpression of lactate dehydrogenase A (LDHA) exacerbate this dysfunction, particularly in pancreatic cancer models. Regulatory T cells (Tregs) not only withstand but exploit elevated lactate. Lactate imported by Tregs fuels oxidative phosphorylation, sustaining their suppressive functions. Concurrently, lactate induces nuclear factor-kappa B (NF-κB)-dependent Foxp3 upregulation, MOESIN lactylation, and enhanced CTLA-4 mRNA splicing regulated by USP39, collectively reinforcing immunosuppressive circuits.

CD8⁺ cytotoxic T lymphocytes face a double metabolic jeopardy in the TME. Extracellular lactate hampers glycolysis by disrupting the NAD⁺/NADH ratio and impeding GLUT10 trafficking to the plasma membrane, thereby depriving these effector cells of necessary energy substrates. Moreover, acidification impairs cytoskeletal rearrangement essential for their infiltration and migration within tumor tissues. However, emerging evidence suggests a nuanced role for lactate: in carefully controlled concentrations, lactate can promote TCF1-dependent stemness programs in select CD8⁺ T-cell subsets, potentially enhancing their longevity and antitumor potential in specific contexts. This dichotomy underscores the complexity of lactate signaling in the immune microenvironment.

Beyond immune cells, stromal components such as cancer-associated fibroblasts (CAFs) significantly contribute to lactate-driven immunomodulation. CAFs respond to lactate exposure by secreting interleukin-8 (IL-8), a potent chemoattractant that promotes recruitment of TAMs and fosters an immunosuppressive niche by restraining CD8⁺ T-cell function and expanding Treg populations. Endothelial cells similarly adapt to the TME, importing lactate via MCT1 to maintain redox homeostasis and stabilize hypoxia-inducible factor 1-alpha (HIF-1α). This stabilization enhances vascular endothelial growth factor (VEGF) production, promoting angiogenesis that supports tumor growth and metastasis. Thus, lactate orchestrates a complex multicellular network that fortifies the immunosuppressive tumor niche.

In light of lactate’s centrality in tumor progression and immune evasion, therapeutic strategies targeting its metabolism are rapidly evolving. The first approach focuses on glycolytic inhibition using agents such as 2-deoxyglucose, oxamate, diclofenac, stiripentol, FX11, and gossypol to suppress LDHA activity and curtail lactate production. Concurrently, inhibitors like syrosingopine and AZD3965 target MCT1/4 to block lactate export, causing toxic intracellular accumulation of lactic acid and metabolic collapse. While promising, these approaches must balance efficacy with toxicity, as glycolysis is vital in many normal tissues.

The second therapeutic avenue leverages immune-potentiating combinations. Augmentation of tumor pH using oral bicarbonate or dichloroacetate-mediated LDHA inhibition alleviates lactate-induced immunosuppression. Further, depletion of ALKBH5, an RNA demethylase implicated in lactate metabolism, sensitizes tumors to immune checkpoint blockade such as anti-PD-1 therapy by reactivating CD8⁺ T and NK cells. These combinational strategies underscore the interplay between metabolic rewiring and immune modulation, paving the way for more effective immunotherapies.

Metabolic repurposing constitutes a third frontier in anti-lactate strategies. Lithium carbonate demonstrates promise by redirecting lactate into CD8⁺ T-cell mitochondria through MCT1 relocalization, rejuvenating oxidative metabolism and restoring cytotoxic function. Additionally, innovative gene-editing nanosystems combining lactate oxidase with signal regulatory protein alpha (SIRPα) fusion proteins have been engineered to simultaneously deplete lactate and reprogram TAMs toward a pro-inflammatory M1 phenotype. These advanced nanotechnologies achieve synergistic tumor phagocytosis and regression in preclinical models, representing a leap forward in metabolic-immunotherapy integration.

Despite these advances, significant challenges hinder translation into clinical success. On-target toxicities of LDHA and MCT inhibitors in glycolysis-dependent normal tissues demand precise therapeutic windows. Tumor metabolic heterogeneity, with some relying more heavily on oxidative phosphorylation than glycolysis, necessitates patient stratification for tailored treatments. Moreover, dosing strategies must avoid collateral damage to antitumor lymphocytes, highlighting the need for refined delivery systems and biomarker-guided therapy.

Looking forward, burgeoning research seeks to harness lactate-responsive drug delivery nanocarriers capable of selectively releasing therapeutics in acidic, lactate-rich TMEs, minimizing systemic exposure. Single-cell transcriptomic and metabolomic mapping of lactate-handling pathways will elucidate cell-type-specific vulnerabilities and intercellular metabolic crosstalk. Clinical validation of lithium-based metabolic adjuvants offers an achievable avenue for immediate impact. Collectively, reframing lactate from a mere metabolic exhaust to a druggable immune checkpoint heralds a paradigmatic shift with transformative potential for next-generation cancer immunotherapies.

This evolving paradigm underscores the profound duality of lactate in cancer biology—both as a metabolic substrate fueling tumor growth and as a cunning architect of immunosuppression. The intricate cellular choreography it orchestrates within the tumor microenvironment challenges conventional views and compels innovative therapeutic strategies. As research deepens, lactic acid stands poised to transition from an overlooked metabolite to a linchpin of metabolic-immunological interventions that promise to reinvigorate antitumor immunity and reshape oncologic treatment landscapes.

Subject of Research: Not applicable

Article Title: Burning lactic acid: a road to revitalizing antitumor immunity

News Publication Date: 9-Jun-2025

Web References: http://dx.doi.org/10.1007/s11684-025-1126-6

Image Credits: Jingwei Ma, Liang Tang, Jingxuan Xiao, Ke Tang, Huafeng Zhang, Bo Huang

Keywords: Health and medicine